REVIEW
Introduction
Asthma, together with allergic rhinitis, are the commonest chronic conditions in children 1 and despite our understanding of the pathophysiology, clinical presentation and having excellent asthma therapies, the disease remains poorly controlled. 2 Asthma is diagnosed on the basis of recurrent 'troublesome lung symptoms, ' (chronic cough and wheeze). 3 Once the diagnosis of asthma is made in a child, and that includes children of all ages, intervention with an inhaled corticosteroid trial is perfectly acceptable. Children require special tools to be able to use inhalers and those include spacers and powder devices.
That is often the easy part of asthma management. What should happen next is where we are letting our patients and children down.
Asthma control
Asthma control means the extent to which the effects of asthma can be seen in the patient, or have been reduced or removed by treatment. 4 Recent Global Initiative for Asthma (GINA) guidelines have suggested that monitoring of asthma control is essential in all asthmatics. 4 (See Figure 1 for GINA assessment of asthma control.) Assessment of control should include symptoms (over the last week and month), and quality of life. In addition, the risk of future exacerbations (spirometry and possibly exhaled nitric oxide), and medication side-effects (oral symptoms and growth in children) must be regularly assessed. Formal tools for assessing control offer the best insight into asthma control. 5 No test is a gold standard and all tests must be used in conjunction to assess control. 6 Recommendation 1. Once an asthmatic is on controller therapy, regular assessment of control is critical. Of equal importance is regular assessment of future risk (exacerbations and side-effects).
Recommendation 2. Control must be formally measured at every visit, and every 3 months.
Recommendation 3.
Formal tools for assessing control include symptom assessments, scores (such as the childhood Asthma Control Test (cACT) 7 and Asthma Control Questionnaire (ACQ)), and spirometry.
Reasons for problematic asthma control
• Incorrect diagnosis.
• Poorly educated patient -non-adherent to regular therapy, inability to use inhaler devices.
• Hidden allergens/sensitisers.
• Hidden triggers -especially environmental tobacco smoke (ETS).
• Co-morbidity -especially allergic rhinitis.
Asthma control is significantly more likely in patients that are educated (know their disease), are regularly taught to use the inhaler device, have a written action plan and educational material (www.asthma.co.za) and are encouraged to use controller medication regularly. 8 
Asthma education
This is the most important aspect of your care of asthmatic children. It is unfortunately the most time-consuming part of your practice. Patient and caregiver education should be such that they take responsibility for a solution that actually works.
The most important points in patient education are listed in Table I . Education is thus time-consuming but is THE unavoidable component that must be provided if you wish to successfully translate good therapy into successful therapy.
Some tools to aiding education include those listed in Table II . There is a potentially endless list of factors that may prevent patients from achieving control of their asthma. Table III lists but a few of these. Some are beyond your control but ensure that you do what you must to ensure control and thereby a normal life for your asthmatic patient. 
Adjusting therapy

Doubling ICS dose or adding a LABA at Step 3
All asthmatic children with moderately severe asthma require a daily ICS (Step 2). Studies and a meta-analysis of paediatric studies (children aged 6-11 years old) for the addition of therapy in asthmatics not well controlled on low dose ICS (Steps 3 and 4), has revealed that adding a LABA improves lung function but does not reduce exacerbations more than double or higher ICS doses. 9, 10 Recommendation 5. For uncontrolled asthma in children older than five years using a low dose ICS, doubling the dose of ICS is preferred to adding a LABA.
LABA use should be considered where ICS local (oral thrush, dysphonia) or systemic side-effects (growth disturbance or disturbance of hypothalamo-pituitary axis function) occur or are suspected. It must be remembered that LABA use is not without side-effects and possible tolerance and/or tachyphylaxis.
Recommendation 6.
Where ICS are causing local or systemic sideeffects, or there is a risk of such side-effects, LABA addition is preferred for poorly-controlled asthma.
Recommendation 7. What is critical in more severe asthma, before the dose of ICS is increased or a new drug is added, is to thoroughly assess the reasons for poor control, including reconsidering the diagnosis, education of patients (especially inhaler technique) and treatment of co-morbidities.
Addition of a leukotriene receptor antagonist (LTRA) at Step 3
One study explored tools to decide on the addition of an LTRA in children, including urinary leukotriene E₄ levels. Higher levels favoured LTRA over LABA step-up therapy. Predictors of differential responses comparing ICS with LTRA step-up therapy were not apparent, probably because of suppression of allergic markers with low-dose ICS treatment. 11 Minimal overlap was seen across FEV₁ and asthma control day predictors, suggesting distinct mechanisms related to lung function and asthma control day responses.
Two meta-analyses of LTRA as add-on therapy in children with more severe asthma were reported and demonstrated that the addition of anti-leukotrienes to ICS is not associated with a statistically significant reduction in the need for rescue oral corticosteroids or hospital admission, compared to the same or an increased dose of ICS in children and adolescents with mild to moderate asthma. 10, 12 Although anti-leukotrienes have been licensed for use in children for over 10 years, the paucity of paediatric trials, the absence of data on preschoolers, and the variability in the reporting of relevant clinical outcomes considerably limit firm conclusions. 12 The LTRA option may be considered where steroid side-effects are suspected or confirmed or where there is parental concern for higher steroid doses +/-LABA use.
Recommendation 8. At present, there is no firm evidence to support the efficacy and safety of anti-leukotrienes as add-on therapy to ICS as a Step-3 option in the therapeutic arsenal for children with uncontrolled asthma symptoms on low-dose ICS. 12 They might be considered as a third-line option instead of doubling the dose of ICS or adding a LABA.
Studies of LABA efficacy and safety are limited in preschool children. 13 Recommendation 9. LABA use has not been well studied in preschool children and efficacy and safety have not been established. They should not be used in these children.
